TSXV:LNGE - Post Discussion
Post by
Digger0144 on Jun 20, 2021 3:54pm
Revenue Generation...iSTRYM...Q1 2022
Clinical Trials will take 2-3 years to complete and receive the necessary approvals from the governing entities.
However, ISTRYM will be the go to in the meantime. It will start to play out in Q1 2022 and the market will begin to interpret the revenue generation model moving forward...this will dictate the value accordingly in terms of the share price...exciting...a new approach to supporting the mental health sector in terms of treatment, support and live monitoring through advanced technology...very nice indeed!
And so it begins! We’re moving forward with enthusiasm and remain on schedule to launch iSTRYM’s MVP to select clinics in Q3 of this year.” Developing the distribution network of content and care protocols for psychedelic drugs allows MINDCURE to create value at all levels of the value chain: client, clinic, protocol developer, and drug developer. Currently in development, iSTRYM will be available to a select number of clinics throughout North America in Q3 2021. The software will be launched broadly and commercially to clinics in Q1 2022. MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression | MINDCURE Health Inc.
Be the first to comment on this post